Schizophrenia is one of the most complex and disabling diseases to affect mankind. Relatively little is known about its nature and its origins, and available treatments are inadequate for most patients. As a result, there are inevitable controversies about what causes it, how to diagnose it, and how best to treat it. However, in the past decade, there has been an explosion of new research, with dramatic discoveries involving genetic etiology and epidemiological risk factors. There has also been a catalog of new drugs coming to market, and controversy about the relative advantages and disadvantages of newer compared with older therapies. In addition, developing technologies in genomics, molecular biology and neuroimaging provide streams of new information. This book represents a definitive, essential, and up-to-date reference text on schizophrenia. It extensively and critically digests and clarifies recent advances and places them within a clinical context. The Editors (one American and one British), highly respected clinical psychiatrists and researchers and acknowledged experts on schizophrenia, have again assembled an outstanding group of contributors from the USA, UK, Europe and Australia, It will be of value to practising psychiatrists and to trainees, as well as to clinical and neuroscience researchers interested in keeping up with this field or coming into it.
The book consists of four sections: descriptive aspects, biological aspects, physical treatments, and psychological and social aspects. It reviews the theoretical controversies over symptomatology, classification and aetiology (particularly pertinent as DSM-V is being developed), the relationship of schizophrenia to the other psychoses, the significance of positive and negative symptoms and pre-morbid personality. It describes a variety of approaches to integrating the vast research data about schizophrenia, including neurodevelopmental, genetic, pharmacological, brain imaging and psychological findings. The biological treatment section reviews the comparative efficacy of various drugs, the management of drug-resistant patients and both neurological and metabolic complications. The final section looks at psychological therapies, social outcomes, and the economics of schizophrenia.
Highly Commended in the Psychiatry section of the 2012 BMA Book Awards.
Contributors vii
Editor’s Note xi
Preface to the 3 Rd Edition xii
Preface to the First Edition xiii
Part 1 Descriptive Aspects 1
1 Concept of schizophrenia: past present and future 3
Nancy C. Andreasen
2 The schizophrenia construct: symptomatic presentation 9
Celso Arango and William T. Carpenter
3 Child and adolescent schizophrenia 24
Chris Hollis and Judith Rapoport
4 Late-onset schizophrenia 47
Robert Howard and Dilip Jeste
5 The schizophrenia spectrum personality disorders 62
Eran Chemerinski and Larry J. Siever
6 The prodrome of schizophrenia 91
Jean Addington and Shôn W. Lewis
7 Course and outcome 104
Wolfram an der Heiden and Heinz Häfner
8 Neurocognitive impairments in schizophrenia: their character and role in symptom formation 142
Terry E. Goldberg Anthony David and James. M. Gold
Part 2 Biological Aspects 163
9 The secondary schizophrenias 165
Thomas M. Hyde and Maria A. Ron
10 Schizophrenia: the epidemiological horizon 185
Assen Jablensky James B. Kirkbride and Peter B. Jones
11 Environmental risk factors for schizophrenia 226
John J. McGrath and Robin M. Murray
12 Classical genetic studies of schizophrenia 245
Brien Riley and Kenneth S. Kendler
13 Genetic associations in schizophrenia 269
Michael C. O’Donovan and Michael J. Owen
14 Intermediate phenotypes in genetic studies of schizophrenia 289
Michael F. Egan and Tyrone D. Cannon
15 Electrophysiology of schizophrenia 311
Georg Winterer and Robert W. McCarley
16 Structural brain imaging in schizophrenia and related populations 334
Stephen M. Lawrie and Christos Pantelis
17 Functional brain imaging in schizophrenia 353
Andreas Meyer-Lindenberg and Edward T. Bullmore
18 Neuropathology of schizophrenia 372
Paul J. Harrison David A. Lewis and Joel E. Kleinman
19 Neurodevelopmental origins of schizophrenia 393
Daniel R. Weinberger and Pat Levitt
20 Dopamine and schizophrenia 413
Anissa Abi-Dargham and Anthony A. Grace
21 Contributions of glutamate and GABA systems to the neurobiology and treatment of schizophrenia 433
John H. Krystal and Bita Moghaddam
22 Animal models of schizophrenia 462
Barbara K. Lipska and Joseph A. Gogos
Part 3 Physical Treatments 483
23 Pharmacology and neuroscience of antipsychotic drugs 485
John L. Waddington Colm M.P. O’Tuathaigh and Gary J. Remington
24 Principles of pharmacological treatment in schizophrenia 515
Thomas R.E. Barnes and Stephen R. Marder
25 Comparative efficacy and effectiveness in the drug treatment of schizophrenia 525
John R. Geddes T. Scott Stroup and Jeffrey A. Lieberman
26 Approaches to treatment-resistant patients 540
Stephan Leucht Christoph U. Correll and John M. Kane
27 Neurological complications of antipsychotic drugs 561
Peter M. Haddad and Venkata S. Mattay
28 Metabolic adverse effects associated with antipsychotic medications 577
John W. Newcomer and Stefan Leucht
Part 4 Psychosocial Aspects 599
29 Schizophrenia and psychosocial stresses 601
Paul E. Bebbington and Elizabeth Kuipers
30 Mental health services for patients with schizophrenia 625
Tom Burns and Bob Drake
31 Societal outcomes in schizophrenia 644
Iain Kooyman and Elizabeth Walsh
32 Psychological treatment of psychosis 666
Gillian Haddock and Will Spaulding
33 Economics of the treatment of schizophrenia 687
Nancy H. Covell Susan M. Essock and Linda K. Frisman
Index 701
Colour plates are found facing page 338
Height:285
Width:229
Spine:37
Weight:2291.00